Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory or Relapsed Non-Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00104923
What this trial is testing

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+1 more
California Cancer Consortium 29
Testing effectiveness (Phase 2)Looking for participantsNCT06533579
What this trial is testing

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc. 32
Testing effectiveness (Phase 2)Study completedNCT00027560
What this trial is testing

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+2 more
Memorial Sloan Kettering Cancer Center 51
Early research (Phase 1)UnknownNCT03921879
What this trial is testing

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Who this might be right for
LymphomaLymphoma, Non-HodgkinLymphoma, B-Cell+4 more
Oncotartis, Inc. 50
Testing effectiveness (Phase 2)Study completedNCT00764517
What this trial is testing

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Indolent Adult Non-Hodgkin Lymphoma+1 more
OHSU Knight Cancer Institute 57
Testing effectiveness (Phase 2)Study completedNCT00059995
What this trial is testing

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center
Not applicableUnknownNCT04870853
What this trial is testing

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Who this might be right for
Recurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+7 more
M.D. Anderson Cancer Center 150
Testing effectiveness (Phase 2)UnknownNCT00740467
What this trial is testing

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Institut Paoli-Calmettes 50
Early research (Phase 1)WithdrawnNCT02238522
What this trial is testing

Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

Who this might be right for
Lymphoproliferative MalignanciesAcute Myeloid Leukemia
Zenith Epigenetics
Testing effectiveness (Phase 2)Study completedNCT03213665
What this trial is testing

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin Lymphoma+38 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)WithdrawnNCT00881387
What this trial is testing

Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

Who this might be right for
Lymphoma
University of Miami
Testing effectiveness (Phase 2)Study completedNCT00005592
What this trial is testing

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Alabama at Birmingham 23
Testing effectiveness (Phase 2)Study completedNCT00119392
What this trial is testing

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt Lymphoma+14 more
Fred Hutchinson Cancer Center 42
Testing effectiveness (Phase 2)Study completedNCT02750670
What this trial is testing

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin's
University Health Network, Toronto 30
Testing effectiveness (Phase 2)Looking for participantsNCT06839456
What this trial is testing

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Who this might be right for
LeukemiaHigh Risk Acute Lymphoblastic LeukemiaHigh Risk Acute Myeloid Leukemia+11 more
Children's Hospital of Philadelphia 100
Testing effectiveness (Phase 2)Looking for participantsNCT04110301
What this trial is testing

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Who this might be right for
Follicular Lymphoma and Marginal Zone Lymphoma
Beijing Mabworks Biotech Co., Ltd. 53
Early research (Phase 1)Study completedNCT00060372
What this trial is testing

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)+59 more
National Cancer Institute (NCI) 21
Early research (Phase 1)Active Not RecruitingNCT00710892
What this trial is testing

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene

Who this might be right for
Acute Lymphoblastic LeukemiaNon-Hodgkin's LymphomaMyelodysplastic Syndrome+1 more
Baylor College of Medicine 10
Testing effectiveness (Phase 2)Study completedNCT02998476
What this trial is testing

Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Who this might be right for
Lymphoma
Incyte Corporation 60
Large-scale testing (Phase 3)Active Not RecruitingNCT05578976
What this trial is testing

Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Genmab 900
Next Page